Unintended Consequences of Approving Unproven Treatments—Hope, Hype, or Harm?
Author:
Affiliation:
1. Department of Neurology, Emory University, Atlanta, Georgia
Publisher
American Medical Association (AMA)
Subject
Neurology (clinical)
Link
https://jamanetwork.com/journals/jamaneurology/articlepdf/2787474/jamaneurology_glass_2022_ed_210023_1644604386.44951.pdf
Reference12 articles.
1. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.;Abe;Amyotroph Lateral Scler Frontotemporal Degener,2014
2. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.;Writing;Lancet Neurol,2017
3. Edaravone: a new treatment for ALS on the horizon?;Hardiman;Lancet Neurol,2017
4. July 2017 ENCALS statement on edaravone.;Al-Chalabi;Amyotroph Lateral Scler Frontotemporal Degener,2017
5. Author response to a Letter to the Editor entitled: Edaravone administration in pivotal clinical study 19 (Authors: Genge, Angela; Brooks, Benjamin).;Turnbull;Amyotroph Lateral Scler Frontotemporal Degener,2019
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis;BMJ;2023-10-27
2. Extending the US Food and Drug Administration’s Postmarket Authorities;JAMA Health Forum;2023-06-09
3. Clinically meaningful change: evaluation of the Rasch-built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) and the ALSFRS-R;Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration;2022-12-07
4. Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design;Neurotherapeutics;2022-07
5. A Proposal to Increase Value and Equity in the Development and Distribution of New Pharmaceuticals;International Journal of Health Services;2022-05-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3